KYTHERA Biopharmaceuticals Inc. (KYTH) announced positive interim results from a Phase IIIb, multicenter, open-label study of ATX-101. The study evaluated the safety and efficacy of ATX-101, a potential first-in-class, non-surgical, injectable drug in Phase III trials for the reduction of unwanted submental fat, or SMF, commonly known as "double chin."
KYTHERA said the results found that ATX-101 is well tolerated and may be effective in reducing SMF by both clinician- and patient-reported outcome measures.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.